Controle Precoce e Intensivo da Glicemia e do Peso Corporal – Estratégias para o Manejo Efetivo do DM2 - MDHealth - Educação Médica Independente
quarta-feira dez 18, 2024

Controle Precoce e Intensivo da Glicemia e do Peso Corporal – Estratégias para o Manejo Efetivo do DM2

Escrito por: MDHealth em 18 de dezembro de 2024

8 min de leitura

Neste vídeo, Dr. João Salles¹ CRM-SP 83123 – RQE 43764 comenta sobre a importância de uma abordagem integrada entre controle...

Quer continuar lendo?

Login Cadastre-se

Referências

  1. Zoungas, S. et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds (2012). Diabetologia, 55, 636-643. https://doi.org/10.1007/s00125-011-2404 

  2. Cavero-Redondo et al. Glycated haemoglobin A1c as a risk factor of cardiovascular outcomes and all-cause mortality in diabetic and non-diabetic populations: a systematic review and meta-analysis (2017). BMJ Open, 7. https://doi.org/10.1136/bmjopen-2017-015949. 

  3. Kim, K. et al. Time to Reach Target Glycosylated Hemoglobin Is Associated with Long-Term Durable Glycemic Control and Risk of Diabetic Complications in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A 6-Year Observational Study (2020). Diabetes & Metabolism Journal, 45, 368 – 378. https://doi.org/10.4093/dmj.2020.0046. 

  4. King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol. 1999 Nov;48(5):643-8. doi: 10.1046/j.1365-2125.1999.00092.x. PMID: 10594464; PMCID: PMC2014359. 

  5. Holman, R.R. et al. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. 2008. N Engl J Med 2008;359:1577-1589. https://doi.org/10.1056/NEJMoa0806470 

  6. Adler, A. I. et al. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91). 2024. The Lancet, Volume 404, Issue 10448, 145 – 155. https://doi.org/10.1016/S0140-6736(24)00537-3 

  7. Michael E. J. L. et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. 2018. The Lancet, Volume 391, Issue 10120, 541551 https://doi.org/10.1016/S0140-6736(17)33102-1 

  8. Juan P. Frías et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes, 2021. J New England Journal of Medicine. P 503-515 V 385 N 6 doi:10.1056/NEJMoa2107519. Acesso em: https://www.nejm.org/doi/full/10.1056/NEJMoa2107519 

Notícias Relacionadas